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Background:We hypothesized that depressed patients would have lower use of guideline-directedmedical ther-
apy for secondary prevention of cardiovascular events following coronary artery bypass grafting (CABG).
Methods:We included all patients who underwent primary isolated CABG in Sweden between 2006 and 2008.
We cross-linked individual level data from national Swedish registers. Preoperative depression was deﬁned as
at least one antidepressant prescription dispensed before surgery.We deﬁnedmedication use as at least two dis-
pensed prescriptions in each medication class (antiplatelet agents, beta-blockers, angiotensin-converting en-
zyme inhibitors (ACEI)/angiotensin II receptor blocker (ARB), and statins) within a rolling 12 month period.
We calculated adjusted risk ratios (RR) for the use of each medication class, and for all four classes, after one
and four years, respectively.
Results:During theﬁrst year after CABG, 93% of all patients (n= 10,586) had at least two dispensed prescriptions
for an antiplatelet agent, 68% for an ACEI/ARB, 91% for a beta-blocker, and 92% for a statin. 57% had prescriptions
for all four medication classes. After four years (n = 4034), 44% had ﬁlled prescriptions for all four medication
classes. Preoperative depression was not signiﬁcantly associated with a lower use of all four medication classes
after one year (RR 0.98, 95% conﬁdence interval (CI) 0.93–1.03) or after four years (RR 0.97, 95% CI 0.86–1.09).
Conclusions: Preoperative depression was not associated with lower use of guideline-directed medical therapy
for secondary prevention after CABG. These ﬁndings suggest that the observed higher mortality following
CABG among depressed patients is not explained by inadequate secondary prevention medication.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Prior research has shown that depression is common in patients
with coronary artery disease and that it is independently associated
with increased cardiovascular morbidity and mortality [1,2]. Approxi-
mately 30 to 45% of all patients with coronary artery disease are suffer-
ing from clinically signiﬁcant depression [3]. Optimal secondary
prevention medications after coronary artery bypass grafting (CABG)
include antiplatelet agents, statins, beta-blockers and angiotensin-
converting inhibitors (ACEI) and are important to reduce the risk forability and freedom from bias of
cic Surgery and Anesthesiology,
eden. Tel.: +46 8 517 728 94;
).
. This is an open access article underrecurrent cardiovascular events [4]. Clinical practice guidelines provide
information and recommendations about patient lifestyle and medical
therapy after CABG [5,6]. Because depression has been established as a
strong and important independent risk factor for recurrent cardiovascu-
lar events andmortality in patients with coronary heart disease, the use
of evidence-based secondary prevention is even more essential among
these patients. However, the coexistence of depression and coronary
heart disease may complicate several aspects of secondary prevention
for coronary heart disease. Psychosocial risk factors such as smoking,
unhealthy food choice, less physical exercise tend to accumulate in the
same individuals and behavioral phenomena common in depressed pa-
tients, e.g. social isolation, a feeling of hopelessness and little belief in
that anything is worthwhile, may act as barriers to secondary preven-
tive efforts [7,8]. Based on these observations, it is not unlikely that de-
pressed patients could face an increased risk of receiving less than
optimal secondary preventionmedications. Lower use of secondarypre-
vention medications may partly explain the higher mortality observed
in patients with depression and coronary heart disease. The hypothesisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Characteristics of the study population.
All patients Antidepressant use
No Yes
Number of patients 10,586 9454 1132
Percent of study population 100 89 11
Age (years) 67.1 (9.2) 67.3 (9.1) 65.2 (9.4)
Female sex (%) 20 19 34
Estimated GFR (mL/min/1.73 m2) 82 (25) 82 (25) 83 (24)
Diabetes mellitus (%) 24 23 33
Atrial ﬁbrillation (%) 3 3 2
Hypertension (%) 59 58 62
Hyperlipidemia (%) 60 59 64
Peripheral vascular disease (%) 8 8 10
Current smoking (%) 18 17 28
COPD (%) 6 6 10
Prior myocardial infarction (%) 46 45 47
Prior heart failure (%) 3 3 4
Prior stroke (%) 5 5 10
Left ventricular function
Ejection fraction N50% (%) 71 71 70
Ejection fraction 30–50% (%) 25 25 26
Ejection fraction b30% (%) 4 4 4
GFR = glomerular ﬁltration rate, CABG = coronary artery bypass grafting,
COPD = chronic obstructive pulmonary disease. Age and GFR are given as means with
standard deviations. All other values are percentages.
38 M. Stenman et al. / IJC Heart & Vessels 3 (2014) 37–42was that depressed patients would have lower use of medications rec-
ommended for secondary prevention of cardiovascular events following
CABG than patients without preoperative depression. The primary aim
was to analyze the association between preoperative depression and
guideline-directed medical therapy after CABG. A secondary aim was
to investigate possible changes inmedication use over time.We also in-




We performed a nationwide population-based cohort study. The
study complied with the Declaration of Helsinki and was approved by
the regional Human Research Ethics Committee in Stockholm, Sweden.
2.2. Study population
We identiﬁed all patients who underwent CABG in Sweden between
2006 and 2008 from the SWEDEHEART (Swedish Web-system for En-
hancement and Development of Evidence-based care in Heart disease
Evaluated According to Recommended Therapies) registry [9]. We ex-
cluded patients who had undergone previous cardiac surgery, and pa-
tients who had concomitant procedures in addition to CABG. We also
excluded patients who underwent surgery within 24 h from decision
to operate. Finally, we excluded patients who died within one year of
surgery, because the outcome of interest was dispensed prescriptions
after a minimum of one year of follow-up. The ﬁnal study population
consisted of patients who underwent primary isolated non-emergent
CABG in Sweden between 2006 and 2008.
2.3. Data sources
The Swedish personal identity number [10] was used by The National
Board of Health and Welfare to cross-link individual level data from
national Swedish registers to assemble the study database. Baseline pa-
tient characteristics were obtained from SWEDEHEART [9], The National
Patient Register, The Prescribed Drug Register and The Total Population
Register (Statistics Sweden). The National Patient Register covers all
diagnoses for all patients hospitalized in Sweden from 1987 [11,12]. The
Prescribed Drug Register [13] was used to identify patients using antide-
pressants (Anatomical Therapeutic Chemical [ATC] code N06A) and who
had at least one dispensed prescription with ATC-code N06A before the
date of surgery. Patients were divided into an exposed group (preopera-
tive antidepressant use) and an unexposed group (no preoperative anti-
depressant use).
2.4. Outcome measures
We identiﬁed patients using the personal identity number who had
at least two dispensed prescriptions with the following ATC-codes:
B01AC (antiplatelet agents), C09 (ACEI/angiotensin receptor blockers
(ARB)), C07 (beta-blockers), and C10AA (statins) from the national
Prescribed Drug Register [13]. The Prescribed Drug Register contains in-
formation about the ATC-code and the date of dispensing covering the
whole population of Sweden since July 2005. The primary outcome
measurewasmedication use deﬁned as at least two dispensed prescrip-
tions in each ATC group (medication class) after at least one year of
follow-up, and at least four years of follow-up, respectively.
2.5. Statistical analyses
To describe baseline characteristics means and standard deviations
were used for continuous variables and frequencies and percentages
for categorical variables. We used modiﬁed Poisson regression [14]with a robust estimator of variance to calculate risk ratios (RR) for
the use of each medication class for depressed patients with non-
depressed patients as reference category. We reported unadjusted
and multivariable adjusted RR with 95% conﬁdence intervals (CI).
The following variables were included in the full multivariable
model: age (continuous variable), sex, current smoking (no/yes),
atrial ﬁbrillation (no/yes), diabetes mellitus (no/yes), hyperlipid-
emia (no/yes), hypertension (no/yes), chronic obstructive pulmo-
nary disease (no/yes), peripheral vascular disease (no/yes), prior
myocardial infarction (no/yes), prior stroke (no/yes), left ventricular
ejection fraction (normal, moderate, or poor), and preoperative
heart failure (no/yes). We also analyzed the distribution of medica-
tion class and medication use in men and women separately. Finally,
we investigated the time trend in secondary prevention medication
by comparing the distribution of medication class for patients who
underwent surgery in 2006 to that of patients who underwent sur-
gery during 2008.2.6. Missing data
Data were missing for some variables: diabetes mellitus (2.8%), cur-
rent smoking (13%), hyperlipidemia (10%), hypertension (10%), periph-
eral vascular disease (0.9%), and preoperative left ventricular function
(0.9%). We used multiple imputation [15] to handle missing data and
imputed 50 datasets. All multivariable analyses were performed on
the imputed data.
Stata version 13.0 (StataCorp LP, College Station, TX)was used for all
data management and statistical analysis.3. Results
From the SWEDEHEART registry 14,032 patients who underwent
CABG between January 2006 and December 2008 were identiﬁed. We
excluded 227 patients who had previous heart surgery, 2261 patients
who had another cardiac procedure than isolated CABG, 660 patients
who were operated within 24 h from decision, and 298 patients who
had a shorter follow-up time than one year. The ﬁnal study population
included 10,586 patients (1132 depressed and 9454 non-depressed)
who underwent primary isolated non-emergent CABG. The baseline
characteristics are presented in Table 1. Female sex, current smoking,
Fig. 1. Distribution of medication use one year after surgery in 10,586 patients who
underwent primary isolated CABG between 2006 and 2008 in Sweden. ACEI =
angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker,
CABG = coronary artery bypass grafting.
Table 2
Crude andmultivariable adjusted associations between antidepressant use and guideline-
directedmedical therapy for secondary prevention in 10,586 patients after CABG between
2006 and 2008 in Sweden. Risk ratios (95% conﬁdence interval).
Antidepressant use
Noa Yes
Number of patients 9454 1132
Antiplatelet agent
Unadjusted 1.00 1.00 (0.99–1.02)
Multivariable adjustedb 1.00 1.00 (0.98–1.02)
ACEI/ARB
Unadjusted 1.00 1.06 (1.02–1.10)
Multivariable adjustedb 1.00 1.02 (0.98–1.06)
Beta-blocker
Unadjusted 1.00 0.99 (0.97–1.01)
Multivariable adjustedb 1.00 0.99 (0.97–1.01)
Statin
Unadjusted 1.00 1.00 (0.99–1.02)
Multivariable adjustedb 1.00 1.00 (0.99–1.02)
All four classes
Unadjusted 1.00 1.03 (0.97–1.08)
39M. Stenman et al. / IJC Heart & Vessels 3 (2014) 37–42a history of stroke, and diabetes were more common in patients with
depression.Multivariable adjustedb 1.00 0.98 (0.93–1.03)
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker.
a Reference category.
b Multivariable adjustment was made for age, gender, current smoking, atrial
ﬁbrillation, diabetes mellitus, hyperlipidemia, hypertension, chronic obstructive
pulmonary disease, peripheral vascular disease, prior myocardial infarction, prior stroke,
left ventricular ejection fraction, and preoperative heart failure.3.1. Medication use
The distribution of secondary preventionmedications after one year
of follow-up is shown in Fig. 1. During the ﬁrst year after CABG, 93% of
all non-depressed patients had at least two dispensed prescriptions
for an antiplatelet agent, 68% for an ACEI/ARB, 91% for a beta-blocker,
and 92% for a statin. Fifty-seven percent of all non-depressed patients
had prescriptions for all four medication classes. Among depressed pa-
tients 94% had at least two dispensed prescriptions for an antiplatelet
agent, 72% for an ACEI/ARB, 90% for a beta-blocker, and 93% for a statin.
Fifty-eight percent of all depressedpatients had prescriptions for all four
medication classes. During the fourth year after CABG, compliance was
generally lower (Fig. 2). Among non-depressed patients, 44% used all
four medication classes, compared to 46% among depressed patients.
Unadjusted and multivariable adjusted associations between depres-
sion and guideline-directed medical therapy for secondary prevention
(antiplatelet agents; ACEI/ARB; beta-blockers; statins and all four classes)
after a minimum of one year of follow-up are shown in Table 2. After
multivariable adjustment, there was no signiﬁcant association between
depression and all four classes of guideline-directed medical therapy for
secondary prevention (RR 0.98, 95% CI: 0.93 to 1.03). The corresponding
adjusted associations between depression and guideline-directed medi-
cal therapy after a minimum of four years of follow-up are shown in
Table 3. After multivariable adjustment, there was no signiﬁcant associa-
tion between depression and all four classes of guideline-directed medi-
cal therapy for secondary prevention (RR 0.97, 95% CI: 0.86 to 1.09) four
years after surgery.Fig. 2. Distribution of medication use four years after surgery in 4034 patients who
underwent primary isolated CABG between 2006 and 2008 in Sweden. ACEI =
angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker,
CABG = coronary artery bypass grafting.3.2. Compliance to guideline-directed medical therapy during four years
after surgery
Adequate compliancewas deﬁned as at least two ﬁlled prescriptions
for each medication class for every rolling 12 months period during a
minimum of four consecutive years. In other words, patients who was
on continuous treatment with an antiplatelet agent, an ACEI/ARB, a
beta-blocker, and a statin during at least four consecutive years after
surgery were deemed adequately compliant to guideline-directed
medical therapy. Among a total of 4034 patients with a minimum of
four years of follow-up, 32% non-depressed, and 32% depressed, had ad-
equate compliance. Adequate compliance was similar in depressed and
non-depressed patients aftermultivariable adjustment (RR 0.91, 95% CI:
0.77 to 1.07).
3.3. Results stratiﬁed by gender
The distribution of medication use and multivariable-adjusted RR
(95% CI) for guideline basedmedication use associatedwith antidepres-
sant use are shown in Table 4. Aftermultivariable adjustment, therewasTable 3
Adjusteda associations between antidepressant use and guideline-directedmedical thera-




Number of patients 3698 336
Antiplatelet agent 1.00 1.01 (0.97–1.05)
ACEI/ARB 1.00 0.97 (0.90–1.05)
Beta-blocker 1.00 0.99 (0.94–1.05)
Statin 1.00 1.08 (1.03–1.12)
All four classes 1.00 0.97 (0.86–1.09)
All four classes during four consecutive years 1.00 0.91 (0.77–1.07)
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker.
a Multivariable adjustment was made for age, gender, current smoking, atrial
ﬁbrillation, diabetes mellitus, hyperlipidemia, hypertension, chronic obstructive
pulmonary disease, peripheral vascular disease, prior myocardial infarction, prior stroke,
left ventricular ejection fraction, and preoperative heart failure.
b Reference category.
Table 4
Distribution of medication use and multivariable-adjusted risk ratios (95% conﬁdence in-
tervals) for guideline-directed medical therapy associated with antidepressant use in
10,586 patients who underwent primary isolated CABG between 2006 and 2008 in





Antidepressant use Antidepressant use
Noa Yes Noa Yes
Distribution (%)
Antiplatelet agent 93 94 94 94
ACEI/ARB 67 72 71 72
Beta-blocker 91 91 93 89
Statin 92 93 93 92
All four classes 56 60 58 58
Risk ratio (95% CI) b
Antiplatelet agent 1.00 1.00 (0.98–1.02) 1.00 1.00 (0.97–1.03)
ACEI/ARB 1.00 1.03 (0.98–1.08) 1.00 1.00 (0.94–1.07)
Beta-blocker 1.00 1.00 (0.97–1.02) 1.00 0.97 (0.93–1.00)
Statin 1.00 1.01 (0.99–1.03) 1.00 1.00 (0.97–1.03)
All four classes 1.00 0.99 (0.93–1.05) 1.00 0.97 (0.88–1.06)
CI = conﬁdence interval, ACEI = angiotensin-converting enzyme inhibitor,
ARB = angiotensin II receptor blocker.
a Reference category.
b Multivariable adjustment was made for age, current smoking, atrial ﬁbrillation,
diabetes mellitus, hyperlipidemia, hypertension, chronic obstructive pulmonary disease,
peripheral vascular disease, prior myocardial infarction, prior stroke, left ventricular
ejection fraction, and preoperative heart failure.
40 M. Stenman et al. / IJC Heart & Vessels 3 (2014) 37–42no signiﬁcant association between depression and all four classes of
guideline-directed medical therapy for secondary prevention in neither
men (RR 0.99, 95% CI: 0.93 to 1.05) or women (RR 1.00, 95% CI: 0.97
(0.88–1.06)).Fig. 3. Distributions of medication use in patients with or without depression who unde
hibitor, ARB = angiotensin II receptor blocker, CABG = coronary artery bypass graftin3.4. Time trends in medication use
Medication use for patients going through surgery in 2006 com-
pared to 2008 is shown in Fig. 3. Antiplatelet agent and beta-blocker
usewas similar for patients going through surgery in 2006 as compared
to those who underwent surgery in 2008. During the same time period,
a small increase in the use of ACEI/ARB and statins was noted.
4. Discussion
Themain ﬁnding in this nation-wide population-based cohort study
of 10,586 patients with coronary heart disease who underwent primary
isolated non-emergent CABG from 2006 to 2008 was that preoperative
depression was not associated with lower use of guideline-directed
medical therapy for secondary prevention of cardiovascular events. Sec-
ondary preventionmedicationswere similar betweenmen andwomen,
and ACEI/ARBs and statins were the only medication classes where a
small increase in use was noted during the study period. Guideline-
directed medical therapy for secondary prevention in patients with
coronary heart disease is important, because approximately half the de-
crease in deaths from coronary heart disease during 1980–2000 in the
United States could be attributable to evidence-basedmedical therapies
[4].
Several studies have investigated the medication use for secondary
prevention in patients with coronary heart disease [16–18]. However,
the use of guideline-directed medical therapy for secondary prevention
medications after CABG in patients with depression has not been thor-
oughly explored.
The use of guideline-directed medical therapy was studied in
European patients with acute coronary syndromes who underwent
PCI [17]. Despite common management guidelines [6], a large variation
in the use of guideline-directedmedical therapywas found between therwent CABG in 2006 compared to 2008. ACEI = angiotensin-converting enzyme in-
g.
41M. Stenman et al. / IJC Heart & Vessels 3 (2014) 37–42different countries. In the Nordic countries, the use of statins was 86%,
beta-blockers 82%, ACEI 64%, and dual antiplatelet therapy 58% after
one year. In our study, the guideline-recommended medication use
was generally higher: the use of statins was 92%, beta-blockers 91%,
an antiplatelet agent 93%, and ACEI/ARB 68%, but it should be noted
that the patient populations were not directly comparable because the
patients in our study underwent CABG, not PCI. It is unclear if patients
with coronary heart disease receive equal medical therapy for second-
ary prevention after CABG and PCI. In contrast to our ﬁndings, second-
ary prevention medication use after CABG and percutaneous coronary
intervention (PCI) was examined in 23,353 patients by Hlatky et al.
[16], and they found that patients who underwent PCI were more
likely to ﬁll a prescription for statins (95.2% vs. 92.9%), ACEI/ARB
(77.6% vs. 70.9%) and beta-blockers (93.9% vs. 93.6%) than patients
who underwent CABG. In another Western European study, secondary
prevention was investigated in a global, high-risk population with
established coronary heart disease [18]. The use of antiplatelet agents
was 94%, beta-blockers 80%, ACEI/ARB 77%, and statins 98%. The gener-
ally high use of secondary prevention medications in this study could
possibly be explained by the design of the study. It was a randomized,
prospective study and patients taking part in this study may be more
compliant to recommended treatments than patients who declined
participation. Kronish et al. [8] studied the effect of depression on
adherence to secondary prevention behaviors and medications at
threemonths after acute coronary syndrome and found that persistent-
ly depressed patients had a lower adherence to medications than per-
sistently non-depressed patients. We studied the association between
depression before CABG and the use of guideline-directedmedical ther-
apy one year after surgery, and in patientswith aminimum follow-up of
four years, respectively. We did not ﬁnd a lower use of secondary
preventionmedications among patients with pre-operative depression,
and thus our results differ from the observations by Kronish et al. [8].
Even though we did not evaluate postoperative depressive status, it
has been shown that preoperative depression is associated with the
highest risk for postoperative depression [19]. Depression is a risk factor
for mortality after CABG [2,20,21] and studies have shown that im-
provement of depression symptoms was consistently associated with
better adherence to medications in patients hospitalized with cardiac
conditions [22]. Future studies should focus on detection and treatment
of depression before CABG, in order to increase the likelihood of
adequate adherence to secondary prevention medications.
4.1. Study limitations
There are several limitations of this study that should be considered.
A certain degree of misclassiﬁcation of exposure was present because
the Swedish national Prescribed Drug Register only contains informa-
tion about prescribed medicines since July 2005. Therefore, some
patients in our study could have been prescribed antidepressants before
that date and consequently classiﬁed into the unexposed group. More-
over, not all patients with clinical depression receive pharmacological
treatment, but instead non-drug therapy e.g. cognitive–behavioral ther-
apy or no treatment at all. Some patients could have been prescribed
anti-depressants for other medical conditions than depression, such as
panic disorder. Other limitations were lack of information regarding
why some patients were not prescribed secondary prevention med-
ications, perhaps due to medical contra-indications. Other factors
which may affect patients' inclination to ﬁll a prescription could be
physician specialty, distance to a pharmacy, social network, and
number of out-patient visits. This information was no available in
the national registers used in this study. We also lacked information
regarding socio-economic status.
A strength of the studywas the nationwide population-based design
which allowed us to include a large number of patients from all centers
performing cardiac surgery in Sweden, which improved the generaliz-
ability of our results.5. Conclusions
Preoperative depression was not associated with lower use of
guideline-directed medical therapy for secondary prevention of cardio-
vascular events in a nationwide population-based cohort study of
10,586 patients who underwent primary isolated non-emergent
CABG. These ﬁndings suggest that the observed highermortality follow-
ing CABG among depressed patients is not explained by inadequate sec-
ondary prevention medication.Funding sources
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